Who benefits most from adjuvant interferon treatment for melanoma?

Helen Gogas*, Huseyin Abali, Paolo A. Ascierto, Lev Demidov, Hubert Pehamberger, Caroline Robert, Jacob Schachter, Alexander M.M. Eggermont, Axel Hauschild, Enrique Espinosa

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Who benefits most from adjuvant interferon treatment for melanoma?'. Together they form a unique fingerprint.

Medicine & Life Sciences